NCT04037254 2026-03-16
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
Clinical Trials
10 trialsNCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
NCT03016741 2026-02-24
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
Phase 4 Active not recruiting
NCT02531516 2026-02-13
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT05498272 2026-01-23
NePtune
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06734130 2026-01-21
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06059118 2026-01-14
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT00329043 2025-12-26
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting